Kwaliz Lite Tablet contains Clonazepam (0.25 mg) and Escitalopram Oxalate (10 mg), combining the therapeutic effects of a benzodiazepine and a selective serotonin reuptake inhibitor (SSRI). Clonazepam acts as an anticonvulsant and anxiolytic agent by enhancing the activity of gamma-aminobutyric acid (GABA) in the central nervous system, thereby providing relief from anxiety, panic disorders, and seizure activity. Escitalopram Oxalate, a potent SSRI, increases serotonin levels in the brain by inhibiting its reuptake, which helps alleviate symptoms of depression and generalized anxiety disorder. Kwaliz Lite is indicated for the management of anxiety disorders, panic attacks, and depressive episodes where both anxiolytic and antidepressant effects are desired. The combination allows for a synergistic approach, addressing multiple neurochemical pathways involved in mood and anxiety regulation. Dosage should be individualized based on patient response and tolerability, with careful monitoring for potential side effects such as sedation, dizziness, gastrointestinal disturbances, and risk of dependence associated with clonazepam. It is contraindicated in patients with hypersensitivity to either component, severe respiratory insufficiency, or acute narrow-angle glaucoma. Use during pregnancy and lactation should be avoided unless clearly necessary. Kwaliz Lite should be prescribed and used under strict medical supervision.